Topic: cell manufacturing
The White House Europe travel ban threatened to interrupt shipments of Novartis’ Kymriah, but Novartis found alternative delivery methods.
Marker Therapeutics says it has overcome an issue in its MultiTAA-specific T cell manufacturing process that led the FDA to stymie an AML trial.
A new commercial-scale gene therapy manufacturing facility is being planned, but not by a biotech or a CDMO. This one will be built by a hospital.
Singapore's Tessa Therapeutics is ready fora commercial-scale facility to manufacture virus-specific T cell (VST) immunotherapies.
A Chinese-American CDMO has raised $60 million but doesn’t intend to hold onto the cash very long. Joinn Biologics will build out biologics capacity.
Harvard and a host of players will build a $50 million clinical supply manufacturing facility near Boston for biotechs working on gene therapies.
Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.
Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job.
Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.
Just weeks after selling its share in Brammer Bio in a $1.7 billion deal, Ampersand has an agreement to buy another CDMO with viral vector expertise.